View these presentation slides showing data from a recent prospective, randomised controlled phase IIIb study for 4F-PCC.
Oral Anticoagulation Reversal
Resources
In This Section
Key Publications
View key article abstracts from several studies below. These investigated different methods of oral anticoagulation management and reversal, such as using plasma, 3- and 4-factor PCC, direct factor Xa inhibitors, and more.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
- Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors
- Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease
- Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal
- Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents
- Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies
- Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants
Educational Slides
A series of educational slide decks detailing four-factor prothrombin complex (4F-PCC) are available to view from this section of the Oral Anticoagulation Reversal Knowledge Centre. Content has been split into two modules, each of which details a specific phase III trial.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase IIIb randomised trial
View this educational slide deck which discusses 4F PCC versus plasma in Vitamin K antagonist reversal in a phase 3b open-label randomised trial.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Job number: KCT16-01-0010
Developed by EPG Health for Medthority in collaboration with CSL Behring, with content provided by CSL Behring.
Not intended for Healthcare Professionals outside Europe.